By API User
The identification of a metabolic pathway could lead to answers and new treatments for those experiencing brain fog because of long COVID. Researchers from UNSW Sydney and St. Vincent’s Hospital have identified a key pathway, involved in inflammation, which appears to be activated in people with long COVID who have symptoms of ‘brain fog’. Scientists … Continued
By API User
FOR IMMEDIATE RELEASE MELBOURNE, VICTORIA, AUSTRALIA, 27 July 2023: A Victorian doctor and pharmacist is seeking an injunction from the Federal Court to stop Pfizer and Moderna from distributing their mRNA Covid-19 vaccines. The plaintiff, Dr Julian Fidge, alleges that Pfizer and Moderna’s mRNA Covid-19 vaccine products contain genetically modified organisms (GMOs)[1], for … Continued
By API User
Amid a sector-wide crisis in financial sustainability, aged care providers around the country are still wondering when hundreds of millions of dollars of emergency COVID expenses will be reimbursed. The Australian Government introduced COVID-19 Support Grants to help providers control outbreaks in their facilities, protecting vulnerable residents and their families, and preventing transmission with the local community. Catholic Health Australia’s Director of Aged Care … Continued
By API User
RESEARCH REVEALS HOW COVID-19 VIRUS INFECTS THE PLACENTA, AND HOW THIS CAN BE PREVENTED In a landmark study published today (TBC) in Nature Cell Biology, Australian researchers, led by Professor Jose Polo from Monash University and the University of Adelaide and University of Melbourne’s Professor Kanta Subbarao from the Peter Doherty Institute for Infection and … Continued
By API User
New research from UNSW Sydney reveals the mental health impacts of the COVID-19 pandemic for women of refugee backgrounds living in Australia. War led Nawal Nadar to flee her home country of Lebanon to Kuwait, then the United Arab Emirates, and finally arriving in Australia in 1998. Ms Nadar is now a maternity liaison … Continued
By API User
PAXLOVID® (nirmatrelvir tablets and ritonavir tablets) will be available on the Pharmaceutical Benefits Scheme (PBS) to people between 50–59 years with mild to moderate COVID-19, with one additional risk factor from 1 July 2023. Wider eligibility criteria mean more Australians most at risk of severe disease may be able to access PBS-subsidised PAXLOVID if they … Continued
By API User
PAXLOVID® (nirmatrelvir tablets and ritonavir tablets) will be available on the Pharmaceutical Benefits Scheme (PBS) to people between 50–59 years with mild to moderate COVID-19, with one additional risk factor from 1 July 2023. Wider eligibility criteria mean more Australians most at risk of severe disease may be able to access PBS-subsidised PAXLOVID if … Continued
By API User
New research shows Australians increasingly report being less likely to take protective measures or act if they suspect they have COVID-19. Over 60s show significant concern about COVID-19, despite 3 in 5 being unaware of their potential eligibility for anti-virals.1 Australians urged to renew their COVID-safe behaviours to help protect their communities. SYDNEY, AUSTRALIA, … Continued
